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Treatment with interleukin-12 (IL-12) induces leishmanicidal activity in experimental
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Materials and Methods Results
Visceral infection. Female BALB/c mice weighing 20-30 g
Anti -IL-12 treatment inhibits antileishmanial resistance.
(Charles River Laboratories, Wilmington, MA) were injected via While untreated and normal IgG -treated mice supported the the tail vein with 10 as late as 2 weeks after infection also induced a measurable effect at week 4 (table 1) . This latter finding, coupled with the data that 4 weeks of continuous anti -IL-12 treatment produced the highest parasite burdens, suggested an ongoing antileishmanial role for endogenous IL-12 throughout the entire 4-week observation period.
Effect of anti -IL-12 on endogenous IFN-g and the tissue immune response to L. donovani. In this model of acquired resistance in BALB/c mice [1, 2] , IFN-g is induced [2, 12] and influxing blood monocytes and T cells are simultaneously assembled to form granulomas that surround fused, parasitized tissue macrophages [2, 13, 14] . While not a direct macrophage activator, IL-12 is considered a principal inducer of IFN-g [8 -10] , a cytokine that in turn not only activates macrophages to kill intracellular L. donovani [2, 3] but also regulates granuloma development [2, 15] . Therefore, we examined serum for IFN-g and hepatic granuloma -forming capacity in mice treated for 4 consecutive weeks with anti -IL-12. The results in table 2 indicated that production of endogenous IFN-g, as measured in the periphery, and optimal assembly of influxing mononuclear cells into mature granulomas in the liver were both clearly dependent on the presence of endogenous IL-12. In control mice, 95% of infected liver foci showed at least 
